Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
Journal: Molecular cancer
Published: August 01, 2013
Significant addition to treatment options for bone metastasis in prostate cancer.
Journal: Cancer biology & therapy
Published: February 17, 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 07, 2012
Showing 1-3 of 3
Last Updated: 09/26/2026